Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

12. Investor Relations & Next Steps

Positioned for Strategic Acquisition in 2026

LPBI Group is a debt-free, founder-led organization with a mature, high-provenance portfolio of intellectual property assets valued at a conservative $xxx–xxx million (including synergistic uplifts). The portfolio is fully documented, ready for due diligence, and purpose-built for transfer of ownership.

Current Status

• 9 GB private multimodal maxi-vault + proprietary 13-part Composition of Methods (COM) Tool Factory
• 13 Hidden Gems functioning as ready-made Small Language Models (SLMs)
• Proven results through three joint articles with Grok (xAI) demonstrating significant causal reasoning uplift
• Strong alignment with industry priorities in oncology, immunology, cardiovascular, infectious disease, and rare diseases

Next Steps – 2026 Outreach Strategy We are actively seeking the right strategic partner through three parallel tracks:

• Private Equity & Strategic Investors – focused on ROI, scalability, and long-term value creation
• Pharma / Biotech Companies – focused on therapeutic area acceleration and internal AI capabilities
• Hyperscalers & Foundation Model Companies – focused on high-quality multimodal data and multi-agent infrastructure

Invitation

We welcome serious inquiries from qualified parties. A full data room (28-slide deck + 33 appendices) is available upon signing a mutual non-disclosure agreement.

The time to act is now — 2026 represents the pivotal window for transferring this unique moat and unlocking its full potential in domain-aware AI in Health.

Contact Aviva Lev-Ari, PhD, RN Founder & Editor-in-Chief Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

Additional Sector Information on Prospecting Targets

• Private Equity and Holding Companies
• Hyperscalers: 

Hyperscalers / Foundation Model Companies

• Grok 4.20’s medicine results (per Elon) + your causal reasoning would accelerate their agentic workflows and multimodal foundation models.

(Discending order) Tencent, NEC, Hitachi, IBM, Baidu, Microsoft, Alphabet (Google DeepMind), Fujitsu, BOE, Canon, NVIDIA, Samsung, Amazon, Alibaba.com, Huawei.

Where LPBI Group’s IP + Grok 4.20 capabilities fit in this active landscape

LPBI + Grok 4.20 fits as a high-provenance data + causal methods moat provider in the AI-native / specialized data layer.

• In Source #1 (patent/competitive landscape): LPBI Group sits in the “AI-native biotech / specialized startups” category — providing the proprietary multimodal corpus + COM that pharma (like Roche) and Big Tech need for patentable AI innovations. You complement Roche’s leadership by supplying the private training data they partner for instead of building internally.
• In Source #2 (value chain): LPBI Group fits in the discovery and clinical R&D layer — your corpus + COM enables the “proprietary multimodal data” and “biology foundation models” that companies like AstraZeneca, Lilly, and Isomorphic Labs are betting billions on. Grok 4.20’s medicine results (per Elon) + your causal reasoning would accelerate their agentic workflows and multimodal foundation models.

Positioning statement for outreach: “LPBI’s 9 GB private multimodal corpus + 13-part COM Tool Factory provides the high-provenance, causally structured data moat that powers the next generation of AI drug discovery platforms and foundation models — directly addressing the proprietary data needs highlighted in recent industry analyses.”

• Focus Pharma

In Source #2 (value chain): LPBI Group fits in the discovery and clinical R&D layer — your corpus + COM enables the “proprietary multimodal data” and “biology foundation models” that companies like AstraZeneca, Lilly, and Isomorphic Labs are betting billions on. Grok 4.20’s medicine results (per Elon) + your causal reasoning would accelerate their agentic workflows and multimodal foundation models.

Pharma / Biotech Companies by Patent Filing of AI Drug Development Programs

(Ascending order) BioNTech, Amgen, Insitro, Sartorius, Juvenescence, BostonGene, Regeneron, Shimadzu, Tempus, Illumina, Sanofi, Recursion, Insilico Medicine, Danaher, Roche, Startups

• Big Pharma

Big Pharma: AI Drug Discovery Indications and Company Name actively pursuing them

• Oncology 45% of generative AI drug discovery revenues:

AstraZeneca, Modella, AWS, Genetech/NVIDIA, Roche, Roche/nevify, Eli Lilly

[LPBI has Cancer Volume 1, 2 and Volume 1 with NLP and interpretation of Expert of NLP results]

• Immunology

SANOFI, Mistral, OpenAI, abbvie, ANTROPIC, Unlearn

[LPBI has a +2500 page book, Series D, Volume 2]

• Endocrinology & metabolic, GLP-AI Engine

Roche, Eli Lilly & NVIDIA, Novo Nordick

[LPBI has a book, SeriesD, Volume 4]

• CNS/Neurology (high clinical failure),

AstraZeneca, Novartis, Microsoft

[LPBI has +300 articles]

• Cardiovascular & Circulatory Diseases

AWS, Amgen

[LPBI has Series A: Six volumes]

• Infectious Disease

GSK Imperial, Pfizer & AWS

[LPBI has a Book: Series D, Volume 3]

• Vaccines: Algorithmic Sequence Optimization

SANOFI- CodonBERT, Moderna, OpenAI, Industry Wide

[LPBI had ~ 200 articles]

• Rare disease Orphan Indication

GSK, Alexion, Pangssa, Takeda cloud, Merck, AstraZeneca, illumine

[LPBI has a Book, Genomics Volume 1]

Pharma / Biotech Companies by Patent Filing of AI Drug Development Programs

• Focus Pharma

(Ascending order) BioNTech, Amgen, Insitro, Sartorius, Juvenescence, BostonGene, Regeneron, Shimadzu, Tempus, Illumina, Sanofi, Recursion, Insilico Medicine, Danaher, Roche, Startups

• Hyperscalers / Foundation Model Companies

(Discending order) Tencent, NEC, Hitachi, IBM, Baidu, Microsoft, Alphabet (Google DeepMind), Fujitsu, BOE, Canon, NVIDIA, Samsung, Amazon, Alibaba.com, Huawei.

@@@

Strategic Outreach Priorities in Genomics & Bioinformatics (Updated April 2026, based on internal assessment by Dr. Stephen J. Williams, CSO)

High Priority Targets (Strongest Prospects)

• Pacific Biosciences – Excellent strategic fit; long-read sequencing leader that could benefit significantly from LPBI’s causal intelligence layer and Rosetta Stone Ontology.
• Merck KGaA – Very strong fit; large, diversified life-sciences company open to external partnerships.
• Oxford Nanopore – Promising; innovative portable sequencing technology with high potential for value-added clinical interpretation.

Medium Priority

• Eurofins – Large and complex organization; could be interested in deeper analytics capabilities.

Low Priority Companies with strong in-house programs or exiting/de-emphasizing the analysis space (10x Genomics, QIAGEN, Illumina, Revvity, Agilent, IQVIA, Promega, etc.).

Competitive Landscape Summary A side-by-side comparison of major bioinformatics and genomics players, including Dr. Williams’ strategic assessment, is available in Appendix #26.

The addition of Slide #29 and Appendix #34 strengthens the Three-Legged Stool Strategy (AJAUS + SLM domain augmentation + spin-off subsidiaries). By systematically curating ~30 daily expressions from the sharpest accelerationist mind in real-time AI, LPBI demonstrates that its Portfolio of IP uniquely combines the largest privately-held multimodal curated training data written by domain-knowledge experts (9 GB) with state-of-the-art AI-driven suites of methodologies — the Composition of Methods (COM).

COM Parts 1–9 supply the methods for data-set creation and curation, while COM Parts 10–15 provide the execution infrastructure by design. COM Part 14 enables autonomous 24/7 refresh of the training data set, and COM Part 15 powers recursive drug discovery factories using self-generated inputs from LPBI’s owned data sets. This vertically integrated foundation directly fuels the spin-off leg of the Three-Legged Stool, creating 13+ high-potential AI companies (InvestAI, OncologyImageAI, ReproGenAI, etc.) that are already aligned with the frontier breakthroughs documented in Slide #29 and Appendix #34.

[Slide #29 URL https://pharmaceuticalintelligence.com/2026-beyond-master-plan/grok-4-aids-exit/2026-slides-content-n-23/]

[Appendix #34 URL https://pharmaceuticalintelligence.com/2026-beyond-master-plan/grok-4-aids-exit/2026-slides-content-n-23/2026-appendices-to-every-slide-n-23/]

Next Steps for Qualified Investors LPBI Group is actively seeking strategic partners and acquirers who recognize the unique value of our 9 GB private multimodal corpus, 15-part COM Tool Factory, and 14 years of expert human curation. Tailored presentations (Grok 4.20 Pivot, ABC Pharma/Biotech, ABC Hyperscalers, and PE/VC versions) are available upon qualified request.